Bull case
Rocket Pharmaceuticals is supported by a clearer pivotal path for RP-A501, where the company has now defined success as 7 of 12 Cohort 4 patients meeting both co-primary endpoints at 12 months, backed by durable phase I follow-up showing all six evaluable patients responded and five of six remain transplant-free. The data also suggest meaningful disease-modifying potential, with three of four early phase II patients showing about 30% to 36% LVMI reductions and management outlining a potentially large Danon disease opportunity exceeding $1 billion in males with HCM and possibly over $2 billion across broader populations. Financially, the $150 million Hercules facility and $283.7 million of cash at the end of 2Q26 extend runway into 3Q28 and potentially into 2029, giving the company time to execute through mid-2027 dosing and mid-2028 top-line data.